Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant
- PMID: 20630123
- DOI: 10.3310/hta14340-02
Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant
Abstract
Background: In April 2009 a novel influenza A virus (AH1N1v) of swine origin (swine flu) emerged, spreading rapidly and achieving pandemic status in June 2009. Pregnant women were identified as being at high risk of severe influenza-related complications and as a priority group for vaccination against AH1N1v. Limited information was available about the maternal and fetal risks of AH1N1v infection or of antiviral drug or AH1N1v vaccine use in pregnancy.
Objectives: To assess rates of and risk factors for adverse outcomes following AH1N1v infection in pregnancy and to assess the adverse effects of the antiviral drugs and vaccines used in prevention and management.
Methods: Prospective national cohort studies were conducted to identify pregnant women who were (1) suspected to be infected with AH1N1v or being treated with antiviral medication in primary care; (2) vaccinated against AH1N1v; and (3) admitted to hospital with confirmed AH1N1v. Characteristics of women with influenza-like illness (ILI) in primary care were compared with those of women without symptoms accepting or declining immunisation. Characteristics of women admitted to hospital with confirmed AH1N1v infection in pregnancy were compared with a historical cohort of over 1200 women giving birth in the UK who were uninfected with AH1N1v. Outcomes examined in hospitalised women included maternal death, admission to an intensive care unit, perinatal mortality and preterm birth. Risk factors for hospital and intensive care unit admission were examined in a full regression model.
Results: The weekly incidence of ILI among pregnant women averaged 51/100,000 over the study period. Antiviral drugs were offered to 4.8% [95% confidence interval (CI) 4.0% to 5.9%] and vaccination to 64.8% (95% CI 64.7% to 68.9%) of registered pregnant women. Ninety pregnant women with ILI presenting in primary care were reported to the research team, 55 of whom were prescribed antiviral drugs and in 42 (76%) cases this was within 2 days of symptom onset. After comparison with 1329 uninfected pregnant women offered vaccination, pre-existing asthma was the only maternal factor identified as increasing risk of ILI presentation [adjusted odds ratio (OR) 2.0, 95% CI 1.0 to 3.9]. Maternal obesity and smoking during pregnancy were also associated with hospital admission with AH1N1v infection. Overall, 241 pregnant women were admitted to hospital with laboratory-confirmed AH1N1v infection. Eighty-three per cent of these women were treated with antiviral agents, but only 6% received antiviral treatment before hospital admission. Treatment within 2 days of symptom onset was associated with an 84% reduction in the odds of admission to an intensive therapy unit (OR 0.16, 95% CI 0.08 to 0.34). Women admitted to hospital with AH1N1v infection were more likely to deliver preterm; a three times increased risk was suggested compared with an uninfected population cohort (OR 3.1, 95% CI 2.1 to 4.5).
Conclusions: Earlier treatment with antiviral agents is associated with improved outcomes for pregnant women and further actions are needed in future pandemics to ensure that antiviral agents and vaccines are provided promptly to pregnant women, particularly in the primary care setting. Further research is needed on longer-term outcomes for infants exposed to AH1N1v influenza, antiviral drugs or vaccines during pregnancy.
Similar articles
-
Influenza and its treatment during pregnancy: A review.J Neonatal Perinatal Med. 2015;8(4):297-306. doi: 10.3233/NPM-15814124. J Neonatal Perinatal Med. 2015. PMID: 26836818 Review.
-
[Influenza H1N1 in obstetric population of a general hospital in Oaxaca].Ginecol Obstet Mex. 2011 Jun;79(6):344-50. Ginecol Obstet Mex. 2011. PMID: 21966825 Spanish.
-
Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)--United States, April 2009-August 2010.MMWR Morb Mortal Wkly Rep. 2011 Sep 9;60(35):1193-6. MMWR Morb Mortal Wkly Rep. 2011. PMID: 21900872
-
Critical illness with AH1N1v influenza in pregnancy: a comparison of two population-based cohorts.BJOG. 2011 Jan;118(2):232-9. doi: 10.1111/j.1471-0528.2010.02736.x. Epub 2010 Oct 13. BJOG. 2011. PMID: 21040393
-
Safety of oseltamivir in pregnancy: a review of preclinical and clinical data.Drug Saf. 2010 Aug 1;33(8):631-42. doi: 10.2165/11536370-000000000-00000. Drug Saf. 2010. PMID: 20635821 Review.
Cited by
-
Defining the balance between optimal immunity and immunopathology in influenza virus infection.Nat Rev Immunol. 2024 May 2. doi: 10.1038/s41577-024-01029-1. Online ahead of print. Nat Rev Immunol. 2024. PMID: 38698083 Review.
-
Variations across Europe in hospitalization and management of pregnant women with SARS-CoV-2 during the initial phase of the pandemic: Multi-national population-based cohort study using the International Network of Obstetric Survey Systems (INOSS).Acta Obstet Gynecol Scand. 2023 Nov;102(11):1521-1530. doi: 10.1111/aogs.14643. Epub 2023 Aug 18. Acta Obstet Gynecol Scand. 2023. PMID: 37594175 Free PMC article.
-
The perinatal health challenges of emerging and re-emerging infectious diseases: A narrative review.Front Public Health. 2023 Jan 5;10:1039779. doi: 10.3389/fpubh.2022.1039779. eCollection 2022. Front Public Health. 2023. PMID: 36684933 Free PMC article. Review.
-
Viral pulmonary infection in pregnancy - Including COVID-19, SARS, influenza A, and varicella.Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt A):17-25. doi: 10.1016/j.bpobgyn.2022.06.006. Epub 2022 Jul 9. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35977871 Free PMC article. Review.
-
Effects of Vertical Transmission of Respiratory Viruses to the Offspring.Front Immunol. 2022 Mar 14;13:853009. doi: 10.3389/fimmu.2022.853009. eCollection 2022. Front Immunol. 2022. PMID: 35359954 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous